公开(公告)号：US20240082206A1

公开(公告)日：2024-03-14

申请号：US17890659

申请日：2022-08-18

申请人： Provectus Pharmatech, Inc. ,  UTI Limited Partnership

发明人： Eric A. Wachter ,  Dominic Rodrigues ,  Satbir Thakur ,  Lucy Swift ,  Chunfen Zhang ,  Mohit Jain ,  Aru Narendran

IPC分类号： A61K31/352 ,  A61K9/00 ,  A61K31/21 ,  A61P35/00

CPC分类号： A61K31/352 ,  A61K9/0019 ,  A61K31/21 ,  A61P35/00

摘要： A method of treating a mammalian subject having hematologic, non-tumorous cancer cells is disclosed. The method comprises the steps of: (A) administering to such a mammalian subject a therapeutically effective amount of a halogenated xanthene, a pharmaceutically acceptable salt or a C1-C4 alkyl ester thereof as a first cancer cytotoxic agent dissolved or dispersed in a pharmaceutically acceptable aqueous medium. The mammalian subject is maintained for a period of time sufficient to induce death of hematologic, non-tumorous cancer cells. A contemplated administration is typically repeated. A contemplated treatment method can also be carried out in conjunction with administration to said mammalian subject of a second therapeutically effective amount of a second, differently-acting cancer cytotoxic agent dissolved or dispersed in a pharmaceutically acceptable medium. The second cancer cytotoxic agent can be a small molecule or an intact antibody or paratope-containing portion thereof.

公开(公告)号：US11857527B2

公开(公告)日：2024-01-02

申请号：US17158328

申请日：2021-01-26

申请人： Société des Produits Nestlé S.A.

发明人： Bernard Cuenoud ,  Mojgan Masoodi

IPC分类号： A61K31/21 ,  A23K20/158 ,  A23L33/12

CPC分类号： A61K31/21 ,  A23K20/158 ,  A23L33/12 ,  A23V2002/00

摘要： A composition comprising medium-chain triglycerides (MCTs) wherein the composition comprises (i) a MCT comprising three fatty acid moieties each with 8 carbon atoms (MCT-C8) and (ii) a MCT comprising three fatty acid moieties each with 10 carbon atoms (MCT-C10); wherein the ratio of MCT-C8 to MCT-C10 is from 10:90 to 90:10 (mol/mol) and wherein the combined amount of MCT-C8 and MCT-C10 make up at least 50 mol % of the MCTs in the composition.

公开(公告)号：US11433043B2

公开(公告)日：2022-09-06

申请号：US16906814

申请日：2020-06-19

申请人： ALFASIGMA S.P.A.

发明人： Mariagrazia Grilli ,  Pier Luigi Canonico ,  Aleardo Koverech

IPC分类号： A61K31/225 ,  A61K31/21 ,  A61K31/205 ,  A61P9/10 ,  A61P21/02 ,  A61P25/00 ,  A61P25/14 ,  A61P25/16 ,  A61P25/28

摘要： The invention described herein is directed to the use of acetyl L-carnitine, or propionyl L-carnitine, or a salt thereof, for preparing a medicament for increasing neurogenesis in neural tissue; in which said increased neurogenesis is useful for preventing central nervous system disorders due to ageing or genetic predisposition.

公开(公告)号：US11351141B2

公开(公告)日：2022-06-07

申请号：US16933191

申请日：2020-07-20

申请人： National Jewish Health

发明人： Brian J. Day ,  Preston E. Bratcher

IPC分类号： A61K31/21 ,  A61K45/06 ,  A61P11/00 ,  A61P31/04

摘要： The present invention generally relates to methods and compositions for treating pulmonary infections and inflammation with a composition comprising selenocyanate, hyposelenocyanite or a selenocyanate conjugate.

公开(公告)号：US20220151988A1

公开(公告)日：2022-05-19

申请号：US17592700

申请日：2022-02-04

申请人： Novartis AG

发明人： William GARNER ,  Margaret GARNER ,  George MINNO ,  David GOODEN

IPC分类号： A61K31/385 ,  A61K9/00 ,  A61K31/21 ,  C07D339/04 ,  C07D343/00

摘要： Compounds, formulations, and methods are provided containing the choline ester of a reducing agent, especially lipoic acid or derivatives thereof. The compounds may be administered via a topical ocular route to treat or prevent oxidative damage.

公开(公告)号：US20220096417A1

公开(公告)日：2022-03-31

申请号：US17448508

申请日：2021-09-22

申请人： G. Pohl-Boskamp GmbH & Co. KG

发明人： Michaela GORATH

IPC分类号： A61K31/21 ,  A61K33/00 ,  A61K31/5377 ,  A61K31/295 ,  A61K31/455 ,  A61K31/34

摘要： The present invention inter alia relates to a method of promoting collateral circulation comprising the step of exposing a subject to a therapeutically effective amount of an NO donor wherein the therapeutically effective amount of the NO donor promotes arteriogenesis sufficient to augment collateral circulation in a physiological or pathological condition.

公开(公告)号：US11160770B2

公开(公告)日：2021-11-02

申请号：US16822466

申请日：2020-03-18

申请人： Indiana University Research and Technology Corporation

发明人： Mark R. Kelley ,  Michael R. Vasko

IPC分类号： A61K31/122 ,  A61K31/12 ,  C07C66/00 ,  C07C235/78 ,  C07D295/185 ,  A61K31/16 ,  A61K31/165 ,  A61K31/19 ,  A61K31/192 ,  A61K31/20 ,  A61K31/21 ,  A61K31/495 ,  A61K31/5375

摘要： Compounds, compositions, and formulations, and accompanying methods useful for treating disorders arising from oxidative DNA damage, including oxidative DNA damage resulting from ionizing radiation or other therapy are described herein.

公开(公告)号：US10792309B2

公开(公告)日：2020-10-06

申请号：US13966153

申请日：2013-08-13

申请人： CATHOLIC UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION

发明人： Mi La Cho ,  Seok-Goo Cho ,  Jung-Yeon Lim ,  Hyun-Sil Park ,  Min-Jung Park

IPC分类号： C07K14/715 ,  A61K35/28 ,  C12N5/0783 ,  C12N5/0775 ,  A61K31/21 ,  A61K39/00 ,  A61K35/17

摘要： The present invention relates to a cell therapy composition for preventing or treating immune disease comprising mesenchymal stem cells and immunoregulatory T-cells as an active ingredient. By infusing mesenchymal stem cells and immunoregulatory T-cells, which are the cellular therapeutic agent of the present invention, into bone marrow transplant animals, rejection to the host is suppressed after the engraftment of the transplanted bone-marrow to thus obtain the effect of reducing graft-versus-host disease and immune disease. Moreover, the effect of such GVHD reduction is much greater than the one obtained when only mesenchymal stem cells are infused. Accordingly, the cell therapy composition of the present invention having the above-mentioned effects can be useful in the prevention or treatment of immune disease.

公开(公告)号：US10772864B2

公开(公告)日：2020-09-15

申请号：US16284461

申请日：2019-02-25

申请人： Biosuccess Biotech Co., Ltd.

发明人： Hung-Fong Chen ,  Zheng Tao Han

IPC分类号： A61K31/23 ,  A61K31/21 ,  A61K31/216 ,  A61K31/235 ,  A61K31/225 ,  A61K45/06 ,  A61K31/573 ,  A61K31/603 ,  A61K31/22 ,  A61K31/381 ,  A61K31/55 ,  A61P25/14 ,  A61P25/28

摘要： Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of chronic and acute conditions. Such conditions may be caused by disease, be symptoms or sequalae of disease. Chronic and acute conditions may be due to viral infections such as HIV and AIDS, neoplastic diseases stroke, kidney disease, urinary incontinence, autoimmune disorders, Parkinson's disease, prostate hypertrophy, aging, or the treatment of such diseases. Additional compositions and methods are provided which employ a phorbol ester or derivative compound in combination with at least one additional agent to yield more effective treatment tools against acute and chronic conditions in mammalian subjects.

公开(公告)号：US20200276145A1

公开(公告)日：2020-09-03

申请号：US16467883

申请日：2017-12-14

申请人： G. POHL-BOSKAMP GMBH & CO. KG

发明人： Marianne BOSKAMP

IPC分类号： A61K31/21 ,  A61K9/00 ,  A61P9/10 ,  A61P43/00

摘要： The present invention pertains to a short acting NO donor for use in a method of reducing side effects of a treatment with said short acting NO donor, comprising administering during a defined time period a gradually increasing amount of said short acting NO donor in an intermitting manner. The present invention is further directed to a short acting NO donor for use in a method for the prevention or treatment of an arterial insufficiency, wherein the NO donor is administered in an intermitting manner, and wherein during the initial phase of the administration, the amount of said short acting NO donor is gradually increased.